Oncorena
Updated: March 03, 2026
CEO - Börje Haraldsson
Country: Sweden | Funding: SEK213.5M (+)
Founded: 2011
Website: https://www.oncorena.se/
Oncorena is developing a new treatment for metastatic kidney cancer based on orellanine - toxin from the Cortinarius mushroom family that exhibits potent cytotoxic activity in kidney cells. The company's candidate, ONC175, is a synthetic orellanine that is administered intravenously and actively and selectively penetrates kidney cancer cells. Preclinical studies have shown that the drug targets kidneys and kidney-derived cancer cells through highly specific uptake. The molecular mechanism of uptake was identified as the presence of solute transporters expressed almost exclusively on kidney cancer cells and renal proximal tubule cells. The company is currently conducting clinical trials of the drug.
Founded: 2011
Website: https://www.oncorena.se/
Oncorena is developing a new treatment for metastatic kidney cancer based on orellanine - toxin from the Cortinarius mushroom family that exhibits potent cytotoxic activity in kidney cells. The company's candidate, ONC175, is a synthetic orellanine that is administered intravenously and actively and selectively penetrates kidney cancer cells. Preclinical studies have shown that the drug targets kidneys and kidney-derived cancer cells through highly specific uptake. The molecular mechanism of uptake was identified as the presence of solute transporters expressed almost exclusively on kidney cancer cells and renal proximal tubule cells. The company is currently conducting clinical trials of the drug.
